Video

Comparing Two MPN Drugs

Author(s):

Trine Alma Knudsen, M.D.

An expert discusses a trial comparing recombinant interferon alpha-2 with hydroxyurea in patients with myeloproliferative neoplasms (MPNs).

Trine Alma Knudsen, M.D., a Ph.D. student in the department of hematology at the Zealand University Hospital in Roskilde, Denmark, discusses the DALIAH trial, which compared recombinant interferon alpha-2 with hydroxyurea in patients with myeloproliferative neoplasms (MPNs).

Initially, there was a higher percentage of patients in the interferon arm who stopped treatment due to toxicities. However, after about 18 months, the researchers saw that there wasn’t much difference between the two drugs. But according to other studies, Knudsen said, staying on interferon might be worth it, as it may prove to be the superior drug after a longer time on treatment.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Minimally Invasive Surgery Transforms Lung Cancer Recovery
Image of woman with text.
Unlike most GI cancers, GIST starts in supportive stromal tissue, not surface cells, and is classified as a sarcoma, says Dr. Weijing Sun.
Six-time cancer survivor Staci Kirk urges patients to trust their bodies and speak up to ensure their needs are understood and addressed throughout cancer care.
Certain treatments may accelerate aging in survivors, but tailored care and healthy habits can help reduce long-term risks, researchers said.
Image of man with text.
Image of woman with text.
Image of man with text.
Image of Staci.
Image of woman, with text.
Related Content
Image of blood.
August 2nd 2025

July Blood Cancer Highlights: Top 5 Updates Patients Should Know

Ryan Scott
As July concludes, the landscape of hematologic oncology continues to evolve, with notable progress in multiple myeloma, myelofibrosis, and CLL.
Cancer Horizons podcast logo
August 2nd 2025

FDA Stops Lung Cancer Trial, CAR-T Cell Therapy Is Cost Effective, Novel Drug Slows Fibrosis

Alex Biese Brielle Benyon
The year 2024 is now underway. After a busy 2023, we’re now looking back at some of the oncology headlines from the new year.
Image of doctor
August 2nd 2025

What Patients With Polycythemia Vera Should Know After ASCO 2025

Dr. Joshua K. Sabari Dr. Raajit K. Rampal
Patients with blood cancers like polycythemia vera, a kind of myeloproliferative neoplasm, may benefit in learning more about recent data from ASCO 2025.
LeVar Burton Helping the MPN Community Through Advocacy and Storytelling
August 2nd 2025

LeVar Burton Helping the MPN Community Through Advocacy and Storytelling

Jamie Cesanek Darlene Dobkowski, MA
On this episode of the “Cancer Horizons” podcast, LeVar Burton sits down with CURE® to talk about the importance of MPN awareness and the power of storytelling in advocacy.
Image of blood cells.
August 2nd 2025

Rusfertide Reduces Phlebotomy Need, Improves Quality of Life in Polycythemia Vera

Ryan Scott
Treatment with the investigational therapeutic rusfertide has proven to be a potential treatment option for patients with polycythemia vera.
From left: Katherine Mast Hagemann, B.S.N., RN, and Dr. Andrew Kuykendall
August 2nd 2025

A Unicorn Among Us

Dr. Andrew Kuykendall
Katherine has an exquisite instinct for understanding that there is a context to each patient’s diagnosis that is just as important to understand.